Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005978 · ClinicalTrials.gov registry record · Phase 1

N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma

A Phase 1 study, sponsored by New Approaches to Neuroblastoma Therapy Consortium.

Completed
Registry status
Phase 1
Development phase

NCT00005978 is a Phase 1 study that has completed, run by New Approaches to Neuroblastoma Therapy Consortium.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005978, a Phase 1 study, has completed, sponsored by New Approaches to Neuroblastoma Therapy Consortium.

COMPLETED
Registry status
Phase 1
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell or bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy. PURPOSE: This phase I trial is studying the side effects and best dose of combination chemotherapy when given before stem cell transplant and radiation therapy in treating patients with neuroblastoma that has not responded to previous treatments.

Interventions

  • DRUG carboplatin
  • DRUG etoposide
  • DRUG melphalan
  • BIOLOGICAL filgrastim
  • PROCEDURE autologous bone marrow transplantation

Trial Details

FieldValue
Start Date 2000-05
Phase Phase 1

What the Registry Record Tells You About NCT00005978

The ClinicalTrials.gov registry entry for NCT00005978 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is New Approaches to Neuroblastoma Therapy Consortium, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.

NCT00005978 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00005978 about?

NCT00005978 is a clinical study titled "N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma". RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell or bone marrow transplantati...

What is the current status of trial NCT00005978?

This trial is currently completed. It is a Phase 1 study. The study started on 2000-05.

What interventions are being tested in trial NCT00005978?

The interventions under investigation include: carboplatin (DRUG), etoposide (DRUG), melphalan (DRUG), filgrastim (BIOLOGICAL), autologous bone marrow transplantation (PROCEDURE).

Who is sponsoring clinical trial NCT00005978?

This trial is sponsored by New Approaches to Neuroblastoma Therapy Consortium, which has 23 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.